Correction to Lancet Diabetes Endocrinol 2021; 9: 743-54

No authors listed

Published Erratum

No authors listed. Lancet Diabetes Endocrinol. 2022 Oct.

. 2022 Oct;10(10):e10.

doi: 10.1016/S2213-8587(22)00223-6. Epub 2022 Aug 18.

No abstract available

Erratum for

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619108 Clinical Trial.